Generated static export from Obsidian-friendly vault markdown
ClinPharm Vault

Program and trial source registry

  • Generated: 2026-04-10T23:47:40.737013+00:00
  • Built from: inventories/ctgov_priority_trials.json, inventories/sponsor_priority_sources.json, inventories/publication_priority_curation.json
  • Purpose: join raw ClinicalTrials.gov caches, sponsor artifacts, and curated publication records into a single auditable registry by program and trial ID.
  • Linking rule: only attach sponsor artifacts or publications to a specific NCT when an explicit identifier is present in the cached metadata or curated manuscript record.

Program summary

Program Class CT.gov trials Sponsor artifacts Primary pubs Supporting pubs Publication status
Barzolvolimab KIT 8 7 3 2 primary_manuscripts_found
BLU-808 KIT 1 5 0 0 no_pubmed_hits
Briquilimab KIT 3 1 0 1 supporting_only
EP262 MRGPRX2 2 1 0 0 search_collisions_only
EVO756 MRGPRX2 2 7 0 0 no_pubmed_hits
Fenebrutinib BTK 2 0 1 3 primary_manuscripts_found
Remibrutinib BTK 16 4 4 2 primary_manuscripts_found
Rilzabrutinib BTK 1 3 1 1 primary_manuscripts_found
SEP-631 MRGPRX2 0 3 0 0 no_pubmed_hits

Barzolvolimab

  • Priority class(es): KIT
  • CT.gov trials: 8
  • Sponsor artifacts: 7
  • Primary publications: 3
  • Supporting publications: 2
  • Publication status: primary_manuscripts_found
  • Publication summary: Strong manuscript coverage across early CIndU proof-of-concept, CSU phase 1b MAD, and CSU phase 2 dose-finding.

Trial registry

  • NCT04538794 | phase: ['PHASE1'] | status: COMPLETED
  • CT.gov cache: raw/clinicaltrials/markdown/NCT04538794.md
  • Primary publications linked: 1
    • PMID 40415544: Anti-KIT Barzolvolimab for Chronic Spontaneous Urticaria.
  • NCT04548869 | phase: ['PHASE1'] | status: COMPLETED
  • CT.gov cache: raw/clinicaltrials/markdown/NCT04548869.md
  • NCT05368285 | phase: ['PHASE2'] | status: COMPLETED
  • CT.gov cache: raw/clinicaltrials/markdown/NCT05368285.md
  • Primary publications linked: 1
    • PMID 41747871: Randomized dose-finding study of anti-KIT barzolvolimab in patients with chronic spontaneous urticaria.
  • NCT05405660 | phase: ['PHASE2'] | status: COMPLETED
  • CT.gov cache: raw/clinicaltrials/markdown/NCT05405660.md
  • NCT06445023 | phase: ['PHASE3'] | status: ACTIVE_NOT_RECRUITING
  • CT.gov cache: raw/clinicaltrials/markdown/NCT06445023.md
  • NCT06455202 | phase: ['PHASE3'] | status: ACTIVE_NOT_RECRUITING
  • CT.gov cache: raw/clinicaltrials/markdown/NCT06455202.md
  • NCT07256392 | phase: ['PHASE3'] | status: RECRUITING
  • CT.gov cache: raw/clinicaltrials/markdown/NCT07256392.md
  • NCT07266402 | phase: ['PHASE3'] | status: RECRUITING
  • CT.gov cache: raw/clinicaltrials/markdown/NCT07266402.md

Primary publications without explicit NCT linkage

  • PMID 36385701: Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria. (linked IDs: NR)

Program-level sponsor artifacts without explicit NCT linkage

  • IR press release positive results (Celldex)
  • IR press release additional positive data (Celldex)
  • AAAAI 2025 CSU poster (Celldex)
  • Phase 2 CIndU ACAAI poster (Celldex)
  • EADV 2024 congress presentation (Celldex)
  • EADV 2025 CSU IgE subgroup poster (Celldex)
  • IR press release PDF additional data (Celldex)

Remaining publication PMIDs not manually curated yet

  • 40074986, 39598410, 40747638, 35166638, 36719690, 40702781, 41654334, 41270830, 33685605

BLU-808

  • Priority class(es): KIT
  • CT.gov trials: 1
  • Sponsor artifacts: 5
  • Primary publications: 0
  • Supporting publications: 0
  • Publication status: no_pubmed_hits
  • Publication summary: No PubMed hits were returned for BLU-808 AND urticaria in this pass.

Trial registry

  • NCT06931405 | phase: ['PHASE2'] | status: RECRUITING
  • CT.gov cache: raw/clinicaltrials/markdown/NCT06931405.md

Program-level sponsor artifacts without explicit NCT linkage

  • Core programs page (Blueprint Medicines)
  • AAAAI WAO 2025 publications page (Blueprint Medicines)
  • AAAAI WAO 2025 BLU-808 WT KIT poster (Blueprint Medicines)
  • AAAAI 2024 BLU-808 WT KIT poster (Blueprint Medicines)
  • Sanofi completes acquisition of Blueprint Medicines (Sanofi)

Briquilimab

  • Priority class(es): KIT
  • CT.gov trials: 3
  • Sponsor artifacts: 1
  • Primary publications: 0
  • Supporting publications: 1
  • Publication status: supporting_only
  • Publication summary: No briquilimab-specific urticaria trial manuscript was identified in this PubMed pass. One broad KIT review hit was captured.

Trial registry

  • NCT06162728 | phase: ['PHASE1', 'PHASE2'] | status: ACTIVE_NOT_RECRUITING
  • CT.gov cache: raw/clinicaltrials/markdown/NCT06162728.md
  • NCT06353971 | phase: ['PHASE1', 'PHASE2'] | status: TERMINATED
  • CT.gov cache: raw/clinicaltrials/markdown/NCT06353971.md
  • NCT06736262 | phase: ['PHASE2'] | status: ACTIVE_NOT_RECRUITING
  • CT.gov cache: raw/clinicaltrials/markdown/NCT06736262.md

Program-level sponsor artifacts without explicit NCT linkage

  • Briquilimab program page (Jasper Therapeutics)

EP262

  • Priority class(es): MRGPRX2
  • CT.gov trials: 2
  • Sponsor artifacts: 1
  • Primary publications: 0
  • Supporting publications: 0
  • Publication status: search_collisions_only
  • Publication summary: The PubMed search returned 3 hits, but title-level review suggests they are broad chronic urticaria reviews rather than direct EP262 manuscripts.

Trial registry

  • NCT06050928 | phase: ['PHASE1'] | status: COMPLETED
  • CT.gov cache: raw/clinicaltrials/markdown/NCT06050928.md
  • NCT06077773 | phase: ['PHASE2'] | status: TERMINATED
  • CT.gov cache: raw/clinicaltrials/markdown/NCT06077773.md

Program-level sponsor artifacts without explicit NCT linkage

  • Pipeline page (Escient Pharmaceuticals)

EVO756

  • Priority class(es): MRGPRX2
  • CT.gov trials: 2
  • Sponsor artifacts: 7
  • Primary publications: 0
  • Supporting publications: 0
  • Publication status: no_pubmed_hits
  • Publication summary: No PubMed hits were returned for EVO756 AND urticaria in this pass.

Trial registry

  • NCT06603220 | phase: ['PHASE2'] | status: COMPLETED
  • CT.gov cache: raw/clinicaltrials/markdown/NCT06603220.md
  • NCT06873516 | phase: ['PHASE2'] | status: RECRUITING
  • CT.gov cache: raw/clinicaltrials/markdown/NCT06873516.md

Program-level sponsor artifacts without explicit NCT linkage

  • MRGPRX2 antagonist program page (Evommune)
  • Clinical trials page (Evommune)
  • CIndU Phase 2 trial initiation PDF (Evommune)
  • GA2LEN 2024 trial results presentation PDF (Evommune)
  • CSU Phase 2b trial initiation PDF (Evommune)
  • CIndU top-line press release PDF (Evommune)
  • EADV 2025 CIndU presentation PDF (Evommune)

Fenebrutinib

  • Priority class(es): BTK
  • CT.gov trials: 2
  • Sponsor artifacts: 0
  • Primary publications: 1
  • Supporting publications: 3
  • Publication status: primary_manuscripts_found
  • Publication summary: One clear primary CSU efficacy manuscript was identified. Remaining hits are mostly reviews, mechanistic/background papers, or search collisions.

Trial registry

  • NCT03137069 | phase: ['PHASE2'] | status: COMPLETED
  • CT.gov cache: raw/clinicaltrials/markdown/NCT03137069.md
  • NCT03693625 | phase: ['PHASE2'] | status: TERMINATED
  • CT.gov cache: raw/clinicaltrials/markdown/NCT03693625.md

Primary publications without explicit NCT linkage

  • PMID 34750553: Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial. (linked IDs: EudraCT 2016-004624-35)

Remaining publication PMIDs not manually curated yet

  • 35667749, 38141832, 35175630, 31446134, 35166638, 35569949, 30015639, 31494233, 41270830, 41654334

Remibrutinib

  • Priority class(es): BTK
  • CT.gov trials: 16
  • Sponsor artifacts: 4
  • Primary publications: 4
  • Supporting publications: 2
  • Publication status: primary_manuscripts_found
  • Publication summary: Strong manuscript coverage. Original CSU clinical data are available for phase 2b, phase 2b extension, phase 3 REMIX week-12/24 results, and 52-week REMIX follow-up.

Trial registry

  • NCT03926611 | phase: ['PHASE2'] | status: COMPLETED
  • CT.gov cache: raw/clinicaltrials/markdown/NCT03926611.md
  • Primary publications linked: 2
    • PMID 36096203: Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria.
    • PMID 37866460: Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks.
  • NCT04109313 | phase: ['PHASE2'] | status: COMPLETED
  • CT.gov cache: raw/clinicaltrials/markdown/NCT04109313.md
  • NCT05030311 | phase: ['PHASE3'] | status: COMPLETED
  • CT.gov cache: raw/clinicaltrials/markdown/NCT05030311.md
  • Primary publications linked: 2
    • PMID 40043237: Remibrutinib in Chronic Spontaneous Urticaria.
    • PMID 41115533: Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies.
  • NCT05032157 | phase: ['PHASE3'] | status: COMPLETED
  • CT.gov cache: raw/clinicaltrials/markdown/NCT05032157.md
  • Primary publications linked: 2
    • PMID 40043237: Remibrutinib in Chronic Spontaneous Urticaria.
    • PMID 41115533: Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies.
  • NCT05048342 | phase: ['PHASE3'] | status: COMPLETED
  • CT.gov cache: raw/clinicaltrials/markdown/NCT05048342.md
  • NCT05170724 | phase: [] | status: AVAILABLE
  • CT.gov cache: raw/clinicaltrials/markdown/NCT05170724.md
  • NCT05513001 | phase: ['PHASE3'] | status: ACTIVE_NOT_RECRUITING
  • CT.gov cache: raw/clinicaltrials/markdown/NCT05513001.md
  • NCT05677451 | phase: ['PHASE3'] | status: RECRUITING
  • CT.gov cache: raw/clinicaltrials/markdown/NCT05677451.md
  • NCT05795153 | phase: ['PHASE3'] | status: COMPLETED
  • CT.gov cache: raw/clinicaltrials/markdown/NCT05795153.md
  • NCT05976243 | phase: ['PHASE3'] | status: ACTIVE_NOT_RECRUITING
  • CT.gov cache: raw/clinicaltrials/markdown/NCT05976243.md
  • NCT06042478 | phase: ['PHASE3'] | status: ACTIVE_NOT_RECRUITING
  • CT.gov cache: raw/clinicaltrials/markdown/NCT06042478.md
  • NCT06865651 | phase: ['PHASE2'] | status: RECRUITING
  • CT.gov cache: raw/clinicaltrials/markdown/NCT06865651.md
  • Sponsor artifacts linked: 1
    • Novartis trial page NCT06865651 (Novartis)
  • NCT06868212 | phase: ['PHASE3'] | status: RECRUITING
  • CT.gov cache: raw/clinicaltrials/markdown/NCT06868212.md
  • NCT07358364 | phase: [] | status: RECRUITING
  • CT.gov cache: raw/clinicaltrials/markdown/NCT07358364.md
  • NCT07358780 | phase: [] | status: RECRUITING
  • CT.gov cache: raw/clinicaltrials/markdown/NCT07358780.md
  • NCT07408219 | phase: [] | status: RECRUITING
  • CT.gov cache: raw/clinicaltrials/markdown/NCT07408219.md

Program-level sponsor artifacts without explicit NCT linkage

  • 2023 Phase III primary endpoints press release (Novartis)
  • 2024 sustained efficacy and safety press release (Novartis)
  • 2026 CIndU Phase III RemIND press release (Novartis)

Remaining publication PMIDs not manually curated yet

  • 35667749, 32083858, 41186128, 38141832, 35175630, 40074986, 40663028, 39598410, 40911497, 40747638, 31446134, 41105846, 40682317

Rilzabrutinib

  • Priority class(es): BTK
  • CT.gov trials: 1
  • Sponsor artifacts: 3
  • Primary publications: 1
  • Supporting publications: 1
  • Publication status: primary_manuscripts_found
  • Publication summary: One clear primary CSU efficacy manuscript was identified, plus later non-primary drug-review coverage.

Trial registry

  • NCT05107115 | phase: ['PHASE2'] | status: COMPLETED
  • CT.gov cache: raw/clinicaltrials/markdown/NCT05107115.md
  • Primary publications linked: 1
    • PMID 40266575: Rilzabrutinib in Antihistamine-Refractory Chronic Spontaneous Urticaria: The RILECSU Phase 2 Randomized Clinical Trial.

Program-level sponsor artifacts without explicit NCT linkage

  • Sanofi pipeline page (Sanofi)
  • Phase 2 CSU results press release (Sanofi)
  • RILECSU Phase 2 hives poster (Sanofi)

Remaining publication PMIDs not manually curated yet

  • 38141832, 35175630, 40074986, 39598410, 40326848, 35166638, 41587611, 41937093

SEP-631

  • Priority class(es): MRGPRX2
  • CT.gov trials: 0
  • Sponsor artifacts: 3
  • Primary publications: 0
  • Supporting publications: 0
  • Publication status: no_pubmed_hits
  • Publication summary: No PubMed hits were returned for SEP-631 AND urticaria in this pass.

Program-level sponsor artifacts without explicit NCT linkage

  • Pipeline page (Septerna)
  • AAAAI 2026 poster PDF (Septerna)
  • Corporate slide deck planned Phase 2b CSU study (Septerna)